Revance Story

<div class='circular--portrait' style='background:#800000;color: #F8F8FF;font-size:4em;'>RT</div>
RVNC -- USA Stock  

USD 24.32  0.36  1.50%

Revance Therapeutics Revenue Per Employee is projected to decrease significantly based on the last few years of reporting. The past year's Revenue Per Employee was at 2,140. The current year Average Equity is expected to grow to about 201.6 M, whereas Net Income Per Employee is forecasted to decline to (891.3 K). As many of us are excited about healthcare space, it is fair to go over Revance Therapeutics. We will check if it is still possible for Revance Therapeutics to minimize net losses this year. This post is to show some fundamental factors affecting Revance Therapeutics' products and services. I will also drop some light on how it may impact the investing outlook for Revance Therapeutics in December.
Published over a month ago
View all stories for Revance Therapeutics | View All Stories
Should you hold on to your Revance Therapeutics position?
Over 96.0% of Revance Therapeutics shares are owned by institutional investors. Institutional ownership of Revance Therapeutics refers to the amount of Revance Therapeutics equity owned by mutual funds, pension funds, insurance companies, investment firms, foundations, or other large entities that manage money on behalf of others. Check out our latest analysis of Revance, including its current ownership diagnostics.

How important is Revance Therapeutics's Liquidity

Revance Therapeutics financial leverage refers to using borrowed capital as a funding source to finance Revance Therapeutics ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Revance Therapeutics financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Revance Therapeutics's total debt and its cash.

What do experts say?

Stock analysis is a method for investors and traders to make buying and selling decisions. By studying and evaluating past and current data, investors and traders attempt to gain an edge in the markets by making informed decisions. It is good to see analyst projects for Revance Therapeutics, but it might be worth checking our own buy vs. sell analysis

Revance Therapeutics exotic insider transaction detected

Legal trades by Revance Therapeutics insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Revance insider trading alert for general transaction of common stock by Rankin Aubrey, President Innovation & Tech, on 2nd of December 2020. This event was filed by Revance Therapeutics Inc with SEC on 2020-12-02. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

Breaking it down a bit more

Revance Therapeutics owns a total of sixty-five million nine hundred thirty thousand outstanding shares. The majority of Revance Therapeutics outstanding shares are owned by third-party entities. These institutional holders are usually referred to as non-private investors looking to secure positions in Revance Therapeutics to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Revance Therapeutics. Please pay attention to any change in the institutional holdings of Revance Therapeutics as this could imply that something significant has changed or about to change at the company. Please note that no matter how much assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.
 2015 2019 2020 (projected)
Interest Expense1.19 M1.24 M1.28 M
Gross Profit300 K345 K458.41 K

Ownership Breakdown

Institutions
95.68%
Retail Investors2.87
Insiders1.45
Institutions95.68

Revance Therapeutics is epected to finish above $25 in December

The skewness is down to 0.85 as of today. Revance Therapeutics shows above-average downside volatility for the selected time horizon. We advise investors to inspect Revance Therapeutics further and ensure that all market timing and asset allocation strategies are consistent with the estimation of Revance Therapeutics future alpha.

The Bottom Line

Whereas some firms within the biotechnology industry are still a little expensive, even after the recent corrections, Revance Therapeutics may offer a potential longer-term growth to investors. The inconsistency in the assessment between current Revance valuation and our trade advice on Revance Therapeutics is due to the recent market swings and your selection of investing horizon. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Revance Therapeutics.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of Revance Therapeutics. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com